[go: up one dir, main page]

BR0111591A - Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes - Google Patents

Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes

Info

Publication number
BR0111591A
BR0111591A BR0111591-0A BR0111591A BR0111591A BR 0111591 A BR0111591 A BR 0111591A BR 0111591 A BR0111591 A BR 0111591A BR 0111591 A BR0111591 A BR 0111591A
Authority
BR
Brazil
Prior art keywords
growth hormone
treatment
recovery
hormone secretion
growth
Prior art date
Application number
BR0111591-0A
Other languages
English (en)
Other versions
BRPI0111591B8 (pt
BR0111591B1 (pt
Inventor
Jean Martinez
Jean-Alain Fehrentz
Vincent Guerlavais
Original Assignee
Zentaris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Ag filed Critical Zentaris Ag
Publication of BR0111591A publication Critical patent/BR0111591A/pt
Publication of BR0111591B1 publication Critical patent/BR0111591B1/pt
Publication of BRPI0111591B8 publication Critical patent/BRPI0111591B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0212—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -N-C-N-C(=0)-, e.g. retro-inverso peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

"COMPOSTOS, COMPOSIçãO FARMACêUTICA, E, MéTODOS PARA ELEVAR O NìVEL DE PLASMA DO HORMÈNIO DE CRESCIMENTO EM UM MAMìFERO, PARA O TRATAMENTO DA DEFICIêNCIA DA SECREçãO DO HORMÈNIO DE CRESCIMENTO, PARA O TRATAMENTO DO RETARDO DO CRESCIMENTO EM CRIANçAS, PARA O TRATAMENTO DE DISTúRBIOS METABóLICOS ASSOCIADOS COM A DEFICIêNCIA DA SECREçãO DO HORMÈNIO DE CRESCIMENTO, EM PARTICULAR EM PACIENTES IDOSOS, E PARA PROMOVER A CURA DE FERIMENTOS, RECUPERAçãO DE CIRURGIA OU RECUPERAçãO DE DOENçAS DEBILITANTES". A invenção diz respeito a compostos da fórmula (I) que são úteis para elevar o nível de plasma do hormónio de crescimento em um mamífero bem como para o tratamento da deficiência da secreção do hormónio de crescimento, retardo do crescimento em crianças e distúrbios metabólicos associados com a deficiência de secreção do hormónio do crescimento.
BRPI0111591A 2000-06-13 2001-06-13 composto, composição farmacêutica, e, usos de um composto BRPI0111591B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21132600P 2000-06-13 2000-06-13
US60/211326 2000-06-13
US23492800P 2000-09-26 2000-09-26
US60/234928 2000-09-26
PCT/EP2001/006717 WO2001096300A1 (en) 2000-06-13 2001-06-13 Growth hormone secretagogues

Publications (3)

Publication Number Publication Date
BR0111591A true BR0111591A (pt) 2003-05-06
BR0111591B1 BR0111591B1 (pt) 2014-02-04
BRPI0111591B8 BRPI0111591B8 (pt) 2021-05-25

Family

ID=26906052

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0111591A BRPI0111591B8 (pt) 2000-06-13 2001-06-13 composto, composição farmacêutica, e, usos de um composto

Country Status (30)

Country Link
US (2) US6861409B2 (pt)
EP (1) EP1289951B1 (pt)
JP (2) JP3522265B2 (pt)
KR (1) KR100825109B1 (pt)
CN (1) CN1232507C (pt)
AR (1) AR029941A1 (pt)
AT (3) ATE362472T1 (pt)
AU (2) AU2001266066B2 (pt)
BG (3) BG66130B1 (pt)
BR (1) BRPI0111591B8 (pt)
CA (1) CA2407659C (pt)
CY (2) CY1107710T1 (pt)
CZ (2) CZ303173B6 (pt)
DE (3) DE60112753T2 (pt)
DK (3) DK1524272T3 (pt)
ES (3) ES2292900T3 (pt)
FR (1) FR19C1044I2 (pt)
HK (1) HK1054224A1 (pt)
HU (1) HU229233B1 (pt)
IL (2) IL153067A0 (pt)
MX (1) MXPA02011899A (pt)
NL (1) NL300999I2 (pt)
NO (1) NO323873B1 (pt)
NZ (1) NZ522280A (pt)
PL (1) PL216676B1 (pt)
PT (2) PT1524272E (pt)
RU (1) RU2270198C2 (pt)
SK (1) SK287169B6 (pt)
TW (2) TW200831076A (pt)
WO (1) WO2001096300A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL216676B1 (pl) * 2000-06-13 2014-05-30 Aeterna Zentaris Gmbh Związki pobudzające wydzielanie hormonu wzrostu, kompozycja farmaceutyczna zawierająca takie związki oraz ich zastosowanie
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7034050B2 (en) * 2004-04-28 2006-04-25 Romano Deghenghi Pseudopeptides growth hormone secretagogues
CA2616396C (en) * 2005-07-22 2013-07-23 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Growth hormone secretagogues
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
GB0603295D0 (en) 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
US7763707B2 (en) * 2006-03-13 2010-07-27 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
EA200901077A1 (ru) 2007-02-09 2010-04-30 Транзим Фарма, Инк. Макроциклические модуляторы грелинового рецептора и их применение
EP2103602A1 (en) 2008-03-17 2009-09-23 AEterna Zentaris GmbH Novel 1,2,4-triazole derivatives and process of manufacturing thereof
US8431642B2 (en) * 2008-06-09 2013-04-30 Exxonmobil Chemical Patents Inc. Polyolefin adhesive compositions and articles made therefrom
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
US8747922B2 (en) 2012-09-19 2014-06-10 Quality Ip Holdings, Inc. Methods and compositions for increasing sex steroids and growth hormones
US10300101B2 (en) 2012-09-19 2019-05-28 Quality IP Holdings, LLC Methods and compositions for enhancing or maintaining fertility
US9198889B2 (en) 2012-09-19 2015-12-01 Quality IP Holdings, LLC Methods for treating post-traumatic stress disorder
US8747921B2 (en) 2012-09-19 2014-06-10 Quality Ip Holdings, Inc. Methods for improving health in humans
US10292957B2 (en) 2012-09-20 2019-05-21 Quality IP Holdings, LLC Compositions and methods for treating fibromyalgia
US9066953B2 (en) 2012-09-20 2015-06-30 Quality IP Holdings, LLC Methods for increasing endurance and fat metabolism in humans
US8715752B2 (en) 2012-09-20 2014-05-06 Quality Ip Holdings, Inc. Compositions for increasing human growth hormone levels
US8747923B2 (en) 2012-09-20 2014-06-10 Quality Ip Holdings, Inc. Methods for improving health in canines
BR112015009107A2 (pt) 2012-10-24 2017-11-14 Daiichi Sankyo Co Ltd agente terapêutico para esclerose lateral amiotrófica, uso de um agonista do receptor do secretagogo do hormônio do crescimento ou um sal farmaceuticamente aceitável do mesmo, e, agonista do receptor do secretagogo do hormônio do crescimento ou sal farmaceuticamente aceitável do mesmo
CN105330720A (zh) * 2014-06-06 2016-02-17 深圳翰宇药业股份有限公司 一种制备马昔瑞林的方法
CN108348501A (zh) * 2015-09-21 2018-07-31 埃莫奈特药业有限责任公司 检测和治疗生长激素缺乏症
US10894072B2 (en) 2017-02-13 2021-01-19 IP Quality Holdings, LLC Compositions and methods for treating fibromyalgia
US10288629B1 (en) 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
IL299918A (en) 2020-07-22 2023-03-01 Aeterna Zentaris Gmbh A screening method for diagnosing growth hormone deficiency in pediatric patients by using macimorelin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0400051B1 (en) * 1988-01-28 1995-05-10 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
WO1995014666A1 (en) * 1993-11-24 1995-06-01 Merck & Co., Inc. Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US6025471A (en) * 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
PL216676B1 (pl) * 2000-06-13 2014-05-30 Aeterna Zentaris Gmbh Związki pobudzające wydzielanie hormonu wzrostu, kompozycja farmaceutyczna zawierająca takie związki oraz ich zastosowanie

Also Published As

Publication number Publication date
BG66130B1 (bg) 2011-06-30
FR19C1044I2 (fr) 2020-07-24
ATE302181T1 (de) 2005-09-15
WO2001096300A1 (en) 2001-12-20
DE60128494D1 (de) 2007-06-28
FR19C1044I1 (pt) 2019-09-08
JP4932132B2 (ja) 2012-05-16
IL153067A0 (en) 2003-06-24
CZ20024095A3 (cs) 2003-05-14
JP2004503536A (ja) 2004-02-05
HUP0302026A2 (hu) 2003-09-29
ES2292900T3 (es) 2008-03-16
CN1232507C (zh) 2005-12-21
BG66217B1 (bg) 2012-05-31
US6861409B2 (en) 2005-03-01
PL216676B1 (pl) 2014-05-30
DE60112753T2 (de) 2006-06-29
ES2250416T3 (es) 2006-04-16
CA2407659C (en) 2010-11-09
BG107379A (bg) 2003-09-30
JP3522265B2 (ja) 2004-04-26
CY1107710T1 (el) 2013-04-18
BRPI0111591B8 (pt) 2021-05-25
TW200831076A (en) 2008-08-01
DK1524272T3 (da) 2007-09-03
NO20025893D0 (no) 2002-12-09
KR100825109B1 (ko) 2008-04-25
ES2288724T3 (es) 2008-01-16
CN1431998A (zh) 2003-07-23
MXPA02011899A (es) 2003-04-22
PT1344773E (pt) 2007-11-27
RU2270198C2 (ru) 2006-02-20
US20040229823A1 (en) 2004-11-18
DK1344773T3 (da) 2007-12-27
CZ305279B6 (cs) 2015-07-15
DK1289951T3 (da) 2005-12-19
DE60112753D1 (de) 2005-09-22
ATE370119T1 (de) 2007-09-15
CZ303173B6 (cs) 2012-05-16
CY1107793T1 (el) 2013-06-19
DE60130025T2 (de) 2008-05-15
AU2001266066B2 (en) 2005-06-30
TWI305529B (en) 2009-01-21
EP1289951B1 (en) 2005-08-17
NL300999I1 (nl) 2019-07-17
AR029941A1 (es) 2003-07-23
EP1289951A1 (en) 2003-03-12
NO323873B1 (no) 2007-07-16
KR20030007889A (ko) 2003-01-23
ATE362472T1 (de) 2007-06-15
HUP0302026A3 (en) 2009-01-28
PT1524272E (pt) 2007-07-25
CA2407659A1 (en) 2001-12-20
AU6606601A (en) 2001-12-24
DE60128494T2 (de) 2008-01-17
BG110771A (bg) 2011-03-31
BG66216B1 (bg) 2012-05-31
HU229233B1 (en) 2013-09-30
NO20025893L (no) 2003-02-10
NL300999I2 (nl) 2019-08-28
NZ522280A (en) 2004-09-24
US7297681B2 (en) 2007-11-20
DE60130025D1 (de) 2007-09-27
BR0111591B1 (pt) 2014-02-04
PL363081A1 (en) 2004-11-15
SK287169B6 (sk) 2010-02-08
HK1054224A1 (en) 2003-11-21
JP2003335752A (ja) 2003-11-28
BG110708A (en) 2010-12-30
SK17562002A3 (sk) 2003-05-02
US20020165343A1 (en) 2002-11-07
IL153067A (en) 2010-05-31

Similar Documents

Publication Publication Date Title
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
CY1105199T1 (el) Θepαπευτικες συνθεσεις για αντιμετωπιση της υπepεκκρισης βλεννας
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
DE60115498D1 (de) Chirurgische vorrichtungen
BR0013540A (pt) Formulações farmacêuticas e seu uso na prevenção de acidente vascular cerebral, diabetes e/ou falha de coração congestiva
NO20076245L (no) Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
ATE305469T1 (de) Sulfonsäure- oder sulfonylamino-n-(heteroaralkyl)-azaheterozyklyl midverbindungen
ATE198550T1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
ES2184145T3 (es) Compuestos de acido sulfonico o sulfonilamino-n-(heteroaralquil)-azaheterociclilamida.
MA28005A1 (fr) Traitement preoperatoire de la douleur postoperatoire
BR0214075A (pt) Dosagem unitária que compreende um análogo de prostaglandina para tratar constipação
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
ATE366581T1 (de) Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
BR0212167A (pt) Forma de dosagem oral de liberação prolongada, uso da mesma, método para a prevenção e/ou tratamento de distúrbios e perturbações médicas, e, processo para a fabricação de uma forma de dosagem de liberação prolongada
BRPI0411237A (pt) método para tratamento da esquizofrenia, e, usos de um agente antipsicótico, e de asenapina
EA200500427A1 (ru) Способы лечения пациентов, страдающих синдромом усталых ног или связанными с ним заболеваниями
ATE535237T1 (de) Verwendung von fts zur behandlung von malignen erkrankungen
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]

Free format text: REPUBLICACAO DO ITEM 9.1- DEFERIMENTO - DA RPI 2201 DE 12/03/12, POR TER SIDO EFETUADA COM INCORRECOES NO TITULO.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/02/2014, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B25D Requested change of name of applicant approved
B25D Requested change of name of applicant approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/06/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 13/06/2021